University of Michigan
Ann Arbor, Michigan, 48109, United States
Location contact
Afton Hassett, PsyD
PRINCIPAL_INVESTIGATOR
Beth Banner
CONTACT
Daniel Clauw, MD
PRINCIPAL_INVESTIGATOR
Sana Shaikh
CONTACT
NCT Number: NCT07731750
Researchers are exploring how certain personal factors, such as symptoms, health history, and lifestyle, may help predict which treatments will work best for someone.
The purpose of this study is to evaluate how well a study algorithm chooses the best treatments for a patient when considering their unique pain characteristics.
Trial opening soon.
Get Notified25 year and older
All sexes
Interventional
Not applicable
Ann Arbor, Michigan, 48109, United States
Afton Hassett, PsyD
PRINCIPAL_INVESTIGATOR
Beth Banner
CONTACT
Daniel Clauw, MD
PRINCIPAL_INVESTIGATOR
Sana Shaikh
CONTACT
During the treatment stages participants may be placed into the following interventions:
After participants are placed in an initial assignment based on a combination of the use of the phenotype based algorithm and randomization, they have the option of continuing on that treatment, switching to another (to be assigned by another randomization combined with use of the algorithm) or adding a second treatment to the first (to be assigned by another randomization combined with use of the algorithm).
Analysis of results will not be a function of the arms listed here, but on whether those allocations were based on the algorithm assigning them initially to their presumed "most effective" treatment; or to a potentially less effective treatment (2nd, 3rd or 4th, choice). These "ranked phenotypic" assignments are masked from participants and researchers until after the trial is completed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After Phenotypic data is collected from participants, the algorithm will use that data to "rank" the likelihood of success of different treatments for an individual; it will then,randomize participants based on two patterns of assignment. And at visit 3, it will re-randomize those participants who wish to add an additional treatment modality or transfer from one modality to another.
A high-contact intervention (10 in-person sessions) involving individualized programs tailored to participant needs and guided by physical therapy best-practice guidelines. Treatment emphasizes home exercise, progressive low-intensity conditioning, and functional endurance.
A moderate-contact telehealth intervention (8 virtual sessions) integrating standard CBT techniques with positive activity modules to enhance engagement, mood, and self-efficacy. Weekly modules focus on pacing, cognitive reframing, relaxation, gratitude, and acts of kindness.
A low-contact, self-guided intervention delivered via the MeTime mobile application, supported by brief staff instruction. Participants practice daily self-acupressure at ten standardized points for approximately 30 minutes per day, stimulating key acupoints associated with pain modulation.
This is a serotonin-norepinephrine reuptake inhibitor (SNRI) FDA-approved for chronic pain. A low-contact pharmacologic intervention consisting of an 8-week dose escalation of 60 mg duloxetine, followed by taper as indicated. Participants initiate medication at home after a standardized orientation, with remote safety and adherence check-ins.
Time frame: T2 (approximately week 6) - T3 (approximately week 15)
The PEG is a three-item survey measure used to assess pain by asking for ratings of Pain intensity, Enjoyment of life, and General activity on a scale of 0-10 over the past week. The final score is the average of the three ratings, with higher scores indicating greater pain severity or interference.
Time frame: T2 (approximately week 6) - T3 (approximately week 15)
Interference from pain is assessed using 6 items covering broad functional domains such as life enjoyment, concentration, daily activities, recreation, tasks, and socializing. The scale uses a recall period of 7 days and a response set ranging from 'Not at all" (1) to "Very much" (5). Total scores are between 4 and 20, with higher scores indicating increased pain interference.
Time frame: T3 (approximately week 15)
Overall perceived benefit of treatment will be assessed using the Patient Global Impression of Change (PGIC).34 This single-item question asks "Overall, how do you feel since the beginning of this phase of the study", and participants respond on a 1 - 7 Likert scale where 1 = markedly improved, 2 = somewhat improved, 3 = mildly improved, 4 = the same, and 5 - 7 are correspondingly "worsened".
Time frame: T2 (approximately week 6) - T3 (approximately week 15)
Real-time 7-day pain severity measure assessed using Qualtrics. In practice, participants initiate EMAs at wake, noon and bed-times. Momentary pain intensity will be assessed with the question: "What is your level of pain right now?" rated on a numerical rating scale from 0 = "no pain" to 10 = "worst pain imaginable."
Time frame: T2 (approximately week 6) - T3 (approximately week 15)
This 10-section scale has good internal consistency, discriminative validity, and sensitivity to change in cLBP. Respondents check the box next to each statement that describes their pain or disability
Contact information is provided by the study sponsor or research team.
Beth Banner
CONTACT
Sana Shaikh
CONTACT
University of Michigan
Other
Algorithm-informed Decision-making to Advance Pain Treatment (ADAPT Study)
Acronym: ADAPT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07462832
Chronic Low-back Pain
View Trial DetailsNCT06778694
Chronic Low-back Pain
View Trial DetailsNCT06544850
Chronic Low-back Pain, Neurologic Manifestations
View Trial DetailsNCT06505161
Chronic Low-back Pain
Alcalá de Henares, Madrid, Spain
View Trial Details